Table 4. Cost effectiveness of screening strategies.
| Strategy | Cost per women in US$ (INR) | QALY per women | Incremental cost in US$ (INR) per QALY gained | Status |
|---|---|---|---|---|
| No screening | 25 (1627) | 23.6418 | ND | |
| VIA: 10 years | 48 (3192) | 23.6837 | 564 (37,339) | ND |
| VIA: 5 Years | 70 (4621) | 23.7097 | 829 (54,881) | ND |
| VIA: 3 Years | 119 (7890) | 23.7311 | 2310 (152,947) | ND |
| HPV: 3 Years | 166 (11,013) | 23.7334 | 20,151 (1,334,010) | ND |
| Pap: 10 Years | 52 (3450) | 23.6786 | D | |
| Pap: 5 years | 77 (5078) | 23.7022 | D | |
| Pap: 3 years | 129 (8545) | 23.7223 | D | |
| HPV: 10 Years | 64 (4231) | 23.6850 | ED | |
| HPV: 5 Years | 98 (6469) | 23.7130 | ED |
*VIA: Visual inspection with acetic acid; Pap: Papanicolaou test; D: Dominated; ND: Non-Dominated; ED: Extended Dominance; ICER: incremental cost effectiveness ratio; QALY: Quality adjusted life years; US$: Unites States Dollar